Perkiomenville, PA, United States of America

Keith S Learn



 

Average Co-Inventor Count = 5.6

ph-index = 8

Forward Citations = 129(Granted Patents)


Location History:

  • Upper Darby, PA (US) (1991)
  • Perkiomenville, PA (US) (1990 - 2021)

Company Filing History:


Years Active: 1990-2021

Loading Chart...
Loading Chart...
Loading Chart...
14 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Keith S. Learn

Introduction

Keith S. Learn is a notable inventor based in Perkiomenville, Pennsylvania. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that inhibit atypical protein kinase C. With a total of 14 patents to his name, Learn's work has the potential to impact the treatment of various proliferative disorders.

Latest Patents

Among his latest patents are the thienopyrimidine inhibitors of atypical protein kinase C. These patents describe a compound of formula (I) or a salt thereof, wherein specific variables are defined. The compounds exhibit PKC inhibitory activity, which may be utilized in treating proliferative disorders. This innovative approach highlights Learn's commitment to advancing medical science through his inventions.

Career Highlights

Throughout his career, Keith S. Learn has worked with prominent companies in the pharmaceutical industry. Notable among these are Cephalon, Inc. and Rhône-Poulenc Rorer Pharmaceuticals Inc. His experience in these organizations has undoubtedly contributed to his expertise and success as an inventor.

Collaborations

Learn has collaborated with several professionals in his field, including Gregory R. Ott and Jason C. Wagner. These partnerships have likely fostered a creative environment that encourages innovation and the development of groundbreaking solutions.

Conclusion

Keith S. Learn's contributions to the field of pharmaceuticals through his patents and collaborations demonstrate his dedication to innovation. His work continues to pave the way for advancements in the treatment of proliferative disorders.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…